Banakh Iouri, Kung Ross, Gupta Sachin, Matthiesson Kati, Tiruvoipati Ravindranath
Pharmacy Department Frankston Hospital Frankston Victoria Australia.
Department of Intensive Care Medicine Frankston Hospital Frankston Victoria Australia.
Clin Case Rep. 2019 Apr 21;7(5):1087-1090. doi: 10.1002/ccr3.2147. eCollection 2019 May.
Sodium-glucose cotransporter 2 inhibitors (SGLT2Is) can be associated with euglycemic diabetic ketoacidosis (eDKA). Severe metabolic acidosis with extreme electrolyte abnormalities can occur with nonsignificant blood glucose elevations in SGLT2I-treated patients. Additional risk factors for eDKA include prolonged fasting, major illness, large weight loss, and reductions in insulin doses.
钠-葡萄糖协同转运蛋白2抑制剂(SGLT2Is)可能与正常血糖性糖尿病酮症酸中毒(eDKA)相关。在接受SGLT2I治疗的患者中,即使血糖升高不显著,也可能出现伴有严重电解质异常的严重代谢性酸中毒。eDKA的其他危险因素包括长期禁食、重大疾病、大幅体重减轻和胰岛素剂量减少。